Christina Tsien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina Tsien has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Yue Cao
Department of Radiation Oncology, University of Michigan Hospital and Health Systems, Ann Arbor, MI
5 shared publicationsDiana Gomez-Hassan
Authors' Affiliations: Departments of 1Radiation Oncology, 2Biostatistics, 3Radiology, 4Neurosurgery, and 5Neurology, University of Michigan, Ann Arbor, Michigan; and 6Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
4 shared publicationsLarry Junck
The University of Michigan, Ann Arbor, MI, USA
4 shared publications- Randall K. Ten Haken
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
4 shared publications Theodore Lawrence
The University of Michigan, Ann Arbor, MI, USA
4 shared publicationsTheodore S. Lawrence
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan
3 shared publications
Latest Publications
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi63
CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES
RRx-001, a novel redox modulator was evaluated as a potential radiosensitizer with WBRT in a multicenter phase I trial for adults with brain metastases. The primary endpoint was to determine MTD. Secondary endpoints included intracranial response rate (IRR), survival and correlation of DCE-MRI parameters with outcome. Dose-escalation was managed by a TITE-CRM design to establish MTD at a 20% estimated DLT rate with four planned dose levels (5, 8.4, 16.5, 27.5 mg/m2). RRx-001 was given pre-WBRT (30 Gy/10 fractions) then twice weekly during WBRT. Target accrual was 30 patients. Correlative DCE-MRI was performed in a subset of patients at baseline, 24 hours post-RRx pre-WBRT, 1 and 4 months. Linear mixed models were used to correlate baseline and change in 24-hour Vp (plasma volume) with change in tumor volume. Between 2/2015-2/2017, 31 patients were enrolled across 5 centers. Two patients dropped out at baseline, and seven were treated with RRx/concurrent temozolomide to be reported separately, for a total of 22 evaluable patients. Median age was 60 years (range 35–85), 13 were male, 55% had melanoma and 23% had NSCLC. No DLTs were observed within 28 days of treatment and 5 patients were treated at the highest dose level. IRR was 50%, five patients survived > 12 months, 3 were alive at last follow-up. Among 10 evaluable patients undergoing DCE-MRI with 64 total lesions at baseline, lower baseline Vp (p=0.002) and reduction in Vp at 24 hours (p=0.001) were associated with reduced tumor volume at 1 and 4 months. RRx-001+WBRT appears well-tolerated in adults with brain metastases, with several long-term survivors and IRR of 50%. Following a single dose of RRx, a reduction in Vp is associated with tumor response at 1 and 4 months, suggesting activity within tumor vasculature and utility as a biomarker of longer-term response.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi63
CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES
RRx-001, a novel redox modulator was evaluated as a potential radiosensitizer with WBRT in a multicenter phase I trial for adults with brain metastases. The primary endpoint was to determine MTD. Secondary endpoints included intracranial response rate (IRR), survival and correlation of DCE-MRI parameters with outcome. Dose-escalation was managed by a TITE-CRM design to establish MTD at a 20% estimated DLT rate with four planned dose levels (5, 8.4, 16.5, 27.5 mg/m2). RRx-001 was given pre-WBRT (30 Gy/10 fractions) then twice weekly during WBRT. Target accrual was 30 patients. Correlative DCE-MRI was performed in a subset of patients at baseline, 24 hours post-RRx pre-WBRT, 1 and 4 months. Linear mixed models were used to correlate baseline and change in 24-hour Vp (plasma volume) with change in tumor volume. Between 2/2015-2/2017, 31 patients were enrolled across 5 centers. Two patients dropped out at baseline, and seven were treated with RRx/concurrent temozolomide to be reported separately, for a total of 22 evaluable patients. Median age was 60 years (range 35–85), 13 were male, 55% had melanoma and 23% had NSCLC. No DLTs were observed within 28 days of treatment and 5 patients were treated at the highest dose level. IRR was 50%, five patients survived > 12 months, 3 were alive at last follow-up. Among 10 evaluable patients undergoing DCE-MRI with 64 total lesions at baseline, lower baseline Vp (p=0.002) and reduction in Vp at 24 hours (p=0.001) were associated with reduced tumor volume at 1 and 4 months. RRx-001+WBRT appears well-tolerated in adults with brain metastases, with several long-term survivors and IRR of 50%. Following a single dose of RRx, a reduction in Vp is associated with tumor response at 1 and 4 months, suggesting activity within tumor vasculature and utility as a biomarker of longer-term response.
- 1 February 2016
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 77 (S 01) , A095
Neurofibromatosis Type 2: Natural History, Outcomes, and Treatment Patterns in a Large Contemporary Cohort
Introduction: Neurofibromatosis type II (NF2) is a challenging inherited cancer condition, which predisposes patients to bilateral vestibular schwannomas, cranial and spinal meningiomas, spinal ependymomas and peripheral nerve schwannomas. A large contemporary cohort of patients with NF2 was reviewed to assess the impact of present-day therapies upon the natural history of this disease. Methods: A retrospective review of 54 patients with NF2 was performed using an IRB-approved brain tumor registry at Washington University in St. Louis over the last two decades. Data collection included demographics, age at diagnosis, burden of cranial and spinal disease, age at onset of deafness, treatments received (medical, surgical and radiation), and outcomes. Statistical analyses included a chi-square test used to compare early vs late age of diagnosis with respect to early vs late onset of unilateral deafness. Results: Median age at diagnosis was 17.5 years (range 3–65); average age at last follow-up was 31 years (range 3–69) for 25 males and 29 females. Of 48 patients who had spinal imaging done, tumors were found in the cervical spine (85.4%), thoracic spine (72.9%), lumbar spine (81.3%), and throughout the spine (60.4%). Median lifetime tumor burden during the time period tracked for this cohort of patient was 6 (range 2–25) intracranial tumors and 6.5 (range 0–32) spinal tumors. The number of spinal tumors likely represents a conservative estimate of small spinal tumors, as many were “too numerous to count.” The median number of lifetime medical and surgical interventions to date related to NF2 was 5 (range 0–17), surgical interventions 3 (range 0–17). The median number of surgical interventions per year was 0.1 (range 0–1.75). Fifteen individuals (27.8%) underwent radiosurgical treatment (9 for meningiomas, 8 for vestibular schwannomas, 3 for both, 2 for other cranial schwannomas, and 2 for spinal tumors). Eleven (20.4%) received bevacizumab (Avastin), an intravenous antibody to vascular endothelial growth factor (VEGF) therapy, two (3.4%) received everolimus (Afinitor), and one (1.9%) received panzopanib (Votrient). Median duration of medical therapy was 16.5 months (range 3–58, n = 12). Four (7.4%) died due to progressive disease or complications of treatment; median age at death was 26.5 years (range 4–38). Median age of onset of unilateral deafness, Gardener-Robertson class 3 or higher, was 21 years (range 7–56, n = 31); median age of bilateral deafness was 24 years (range 13–61, n = 15). Using a chi-square test (p < .001), it was determined that patients diagnosed with NF2 at an early age (<=20 years) had earlier onset of unilateral deafness (median age 15, range 7–20), compared with those diagnosed at a later age (unilateral deafness in latter group at median age 31, range 21–56) Conclusion: NF2 is a complex tumor predisposition disorder associated with bilateral vestibular schwannomas and numerous other tumors of the nervous system. NF2 patients typically undergo large numbers of surgical interventions and other treatments with an increasing number undergoing medical treatment such as bevacizumab in recent years. Patients diagnosed at a younger age are more likely to have an earlier age of onset of unilateral deafness.
- 1 February 2016
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 77 (S 01) , A095
Neurofibromatosis Type 2: Natural History, Outcomes, and Treatment Patterns in a Large Contemporary Cohort
Introduction: Neurofibromatosis type II (NF2) is a challenging inherited cancer condition, which predisposes patients to bilateral vestibular schwannomas, cranial and spinal meningiomas, spinal ependymomas and peripheral nerve schwannomas. A large contemporary cohort of patients with NF2 was reviewed to assess the impact of present-day therapies upon the natural history of this disease. Methods: A retrospective review of 54 patients with NF2 was performed using an IRB-approved brain tumor registry at Washington University in St. Louis over the last two decades. Data collection included demographics, age at diagnosis, burden of cranial and spinal disease, age at onset of deafness, treatments received (medical, surgical and radiation), and outcomes. Statistical analyses included a chi-square test used to compare early vs late age of diagnosis with respect to early vs late onset of unilateral deafness. Results: Median age at diagnosis was 17.5 years (range 3–65); average age at last follow-up was 31 years (range 3–69) for 25 males and 29 females. Of 48 patients who had spinal imaging done, tumors were found in the cervical spine (85.4%), thoracic spine (72.9%), lumbar spine (81.3%), and throughout the spine (60.4%). Median lifetime tumor burden during the time period tracked for this cohort of patient was 6 (range 2–25) intracranial tumors and 6.5 (range 0–32) spinal tumors. The number of spinal tumors likely represents a conservative estimate of small spinal tumors, as many were “too numerous to count.” The median number of lifetime medical and surgical interventions to date related to NF2 was 5 (range 0–17), surgical interventions 3 (range 0–17). The median number of surgical interventions per year was 0.1 (range 0–1.75). Fifteen individuals (27.8%) underwent radiosurgical treatment (9 for meningiomas, 8 for vestibular schwannomas, 3 for both, 2 for other cranial schwannomas, and 2 for spinal tumors). Eleven (20.4%) received bevacizumab (Avastin), an intravenous antibody to vascular endothelial growth factor (VEGF) therapy, two (3.4%) received everolimus (Afinitor), and one (1.9%) received panzopanib (Votrient). Median duration of medical therapy was 16.5 months (range 3–58, n = 12). Four (7.4%) died due to progressive disease or complications of treatment; median age at death was 26.5 years (range 4–38). Median age of onset of unilateral deafness, Gardener-Robertson class 3 or higher, was 21 years (range 7–56, n = 31); median age of bilateral deafness was 24 years (range 13–61, n = 15). Using a chi-square test (p < .001), it was determined that patients diagnosed with NF2 at an early age (<=20 years) had earlier onset of unilateral deafness (median age 15, range 7–20), compared with those diagnosed at a later age (unilateral deafness in latter group at median age 31, range 21–56) Conclusion: NF2 is a complex tumor predisposition disorder associated with bilateral vestibular schwannomas and numerous other tumors of the nervous system. NF2 patients typically undergo large numbers of surgical interventions and other treatments with an increasing number undergoing medical treatment such as bevacizumab in recent years. Patients diagnosed at a younger age are more likely to have an earlier age of onset of unilateral deafness.
- 1 July 2014
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 24 (3) , 218-226
Clinical Applications for Diffusion Magnetic Resonance Imaging in Radiotherapy
- 1 July 2014
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 24 (3) , 218-226
Clinical Applications for Diffusion Magnetic Resonance Imaging in Radiotherapy
- Open Access
- 21 August 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 204
Concurrent whole brain radiotherapy and bortezomib for brain metastasis
Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis.
- 21 August 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 204
Open AccessConcurrent whole brain radiotherapy and bortezomib for brain metastasis
Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis.
- 21 August 2012
- Published by Wiley in Head & Neck
- Vol. 35 (9) , 1323-1330
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma
Background: The purpose of this study was to determine if there are differences in biomarker modulation and epidermal growth factor receptor (EGFR) degradation between the tumor and the normal mucosa after treatment with an EGFR inhibitor, erlotinib, in head and neck cancer.Methods: Patients with primary oral cavity squamous cell cancers received a course of erlotinib, 150 mg every day for 7 days before surgical resection. Tumor and normal mucosa biopsies were obtained both pre‐erlotinib and post‐erlotinib. Changes in known markers of EGFR activity (phospho, AKT, STAT3) were measured by immunoblotting, whereas changes in tissue distribution were analyzed by immunohistochemical analysis.Results: Twelve patients were enrolled; 7 had evaluable paired tumors and normal mucosa biopsies pretreatment and posttreatment. Expression of EGFR was higher in tumors compared to the normal mucosa (p = .005). Erlotinib administration was associated with marked inhibition of phosphorylated epidermal growth factor receptor (pEGFR) and reduction in total EGFR protein (p = .004, p = .007) in tumors, whereas there was heterogeneity in EGFR inhibition in the normal mucosa (p = .10 [pEGFR], and p = .07 [EGFR]). Reduced levels of pSrc and pSTAT3 and enhanced p27 levels were noted in tumors after erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor cells after prolonged treatment with erlotinib.Conclusion: Our results show that EGFR inhibition by erlotinib led to a marked reduction in EGFR protein levels in patients. Differential effects of erlotinib on tumors compared to the normal mucosa suggest there may be individual patient heterogeneity. These preliminary data suggest EGFR degradation should be further analyzed as a potential biomarker in selecting patients likely to benefit from EGFR inhibitors. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
- 21 August 2012
- Published by Wiley in Head & Neck
- Vol. 35 (9) , 1323-1330
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma
Background: The purpose of this study was to determine if there are differences in biomarker modulation and epidermal growth factor receptor (EGFR) degradation between the tumor and the normal mucosa after treatment with an EGFR inhibitor, erlotinib, in head and neck cancer.Methods: Patients with primary oral cavity squamous cell cancers received a course of erlotinib, 150 mg every day for 7 days before surgical resection. Tumor and normal mucosa biopsies were obtained both pre‐erlotinib and post‐erlotinib. Changes in known markers of EGFR activity (phospho, AKT, STAT3) were measured by immunoblotting, whereas changes in tissue distribution were analyzed by immunohistochemical analysis.Results: Twelve patients were enrolled; 7 had evaluable paired tumors and normal mucosa biopsies pretreatment and posttreatment. Expression of EGFR was higher in tumors compared to the normal mucosa (p = .005). Erlotinib administration was associated with marked inhibition of phosphorylated epidermal growth factor receptor (pEGFR) and reduction in total EGFR protein (p = .004, p = .007) in tumors, whereas there was heterogeneity in EGFR inhibition in the normal mucosa (p = .10 [pEGFR], and p = .07 [EGFR]). Reduced levels of pSrc and pSTAT3 and enhanced p27 levels were noted in tumors after erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor cells after prolonged treatment with erlotinib.Conclusion: Our results show that EGFR inhibition by erlotinib led to a marked reduction in EGFR protein levels in patients. Differential effects of erlotinib on tumors compared to the normal mucosa suggest there may be individual patient heterogeneity. These preliminary data suggest EGFR degradation should be further analyzed as a potential biomarker in selecting patients likely to benefit from EGFR inhibitors. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
- 1 January 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (1) , 273-279
Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma
Purpose: To determine the maximum-tolerated dose (MTD) of radiation (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma (GBM), to estimate their progression-free (PFS) and overall survival (OS), and to assess the role of 11C methionine PET (MET-PET) imaging in predicting recurrence. Experimental Design: Intensity-modulated RT (IMRT) doses of 66 to 81 Gy, assigned to patients by the time-to-event continual reassessment method, were delivered over 6 weeks with concurrent daily temozolomide (75 mg/m2) followed by adjuvant cyclic temozolomide (200 mg/m2 d1-5 q28d ×6 cycles). Treatment was based on gadolinium-enhanced MRI. Pretreatment MET-PET scans were obtained for correlation with eventual sites of failure. Results: A total of 38 patients were analyzed with a median follow-up of 54 months for patients who remain alive. Late CNS grade ≥III toxicity was observed at 78 (2 of 7 patients) and 81 Gy (1 of 9 patients). None of 22 patients receiving 75 or less Gy developed RT necrosis. Median OS and PFS were 20.1 (14.0–32.5) and 9.0 (6.0–11.7) months, respectively. Twenty-two of 32 patients with pretreatment MET-PET uptake showed uptake beyond the contrast-enhanced MRI. Patients whose treatment did not include the region of increased MET-PET uptake showed an increased risk of noncentral failure (P < 0.001). Conclusions: Patients with GBM can safely receive standard temozolomide with 75 Gy in 30 fractions, delivered using IMRT. The median OS of 20.1 months is promising. Furthermore, MET-PET appears to predict regions of high risk of recurrence not defined by MRI, suggesting that further improvements may be possible by targeting metabolically active regions. Clin Cancer Res; 18(1); 273–9. ©2011 AACR.
- 1 January 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (1) , 273-279
Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma
Purpose: To determine the maximum-tolerated dose (MTD) of radiation (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma (GBM), to estimate their progression-free (PFS) and overall survival (OS), and to assess the role of 11C methionine PET (MET-PET) imaging in predicting recurrence. Experimental Design: Intensity-modulated RT (IMRT) doses of 66 to 81 Gy, assigned to patients by the time-to-event continual reassessment method, were delivered over 6 weeks with concurrent daily temozolomide (75 mg/m2) followed by adjuvant cyclic temozolomide (200 mg/m2 d1-5 q28d ×6 cycles). Treatment was based on gadolinium-enhanced MRI. Pretreatment MET-PET scans were obtained for correlation with eventual sites of failure. Results: A total of 38 patients were analyzed with a median follow-up of 54 months for patients who remain alive. Late CNS grade ≥III toxicity was observed at 78 (2 of 7 patients) and 81 Gy (1 of 9 patients). None of 22 patients receiving 75 or less Gy developed RT necrosis. Median OS and PFS were 20.1 (14.0–32.5) and 9.0 (6.0–11.7) months, respectively. Twenty-two of 32 patients with pretreatment MET-PET uptake showed uptake beyond the contrast-enhanced MRI. Patients whose treatment did not include the region of increased MET-PET uptake showed an increased risk of noncentral failure (P < 0.001). Conclusions: Patients with GBM can safely receive standard temozolomide with 75 Gy in 30 fractions, delivered using IMRT. The median OS of 20.1 months is promising. Furthermore, MET-PET appears to predict regions of high risk of recurrence not defined by MRI, suggesting that further improvements may be possible by targeting metabolically active regions. Clin Cancer Res; 18(1); 273–9. ©2011 AACR.
- 1 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (13) , 2293-2299
Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma
Purpose: To assess whether a new method of quantifying therapy-associated hemodynamic alterations may help to distinguish pseudoprogression from true progression in patients with high-grade glioma. Patients and Methods: Patients with high-grade glioma received concurrent chemoradiotherapy. Relative cerebral blood volume (rCBV) and blood flow (rCBF) maps were acquired before chemoradiotherapy and at week 3 during treatment on a prospective institutional review board–approved study. Pseudoprogression was defined as imaging changes 1 to 3 months after chemoradiotherapy that mimic tumor progression but stabilized or improved without change in treatment or for which resection revealed radiation effects only. Clinical and conventional magnetic resonance (MR) parameters, including average percent change of rCBV and CBF, were evaluated as potential predictors of pseudoprogression. Parametric response map (PRM), an innovative, voxel-by-voxel method of image analysis, was also performed. Results: Median radiation dose was 72 Gy (range, 60 to 78 Gy). Of 27 patients, stable disease/partial response was noted in 13 patients and apparent progression was noted in 14 patients. Adjuvant temozolomide was continued in all patients. Pseudoprogression occurred in six patients. Based on PRM analysis, a significantly reduced blood volume (PRMrCBV) at week 3 was noted in patients with progressive disease as compared with those with pseudoprogression (P < .01). In contrast, change in average percent rCBV or rCBF, MR tumor volume changes, age, extent of resection, and Radiation Therapy Oncology Group recursive partitioning analysis classification did not distinguish progression from pseudoprogression. Conclusion: PRMrCBV at week 3 during chemoradiotherapy is a potential early imaging biomarker of response that may be helpful in distinguishing pseudoprogression from true progression in patients with high-grade glioma.
- 1 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (13) , 2293-2299
Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma
Purpose: To assess whether a new method of quantifying therapy-associated hemodynamic alterations may help to distinguish pseudoprogression from true progression in patients with high-grade glioma. Patients and Methods: Patients with high-grade glioma received concurrent chemoradiotherapy. Relative cerebral blood volume (rCBV) and blood flow (rCBF) maps were acquired before chemoradiotherapy and at week 3 during treatment on a prospective institutional review board–approved study. Pseudoprogression was defined as imaging changes 1 to 3 months after chemoradiotherapy that mimic tumor progression but stabilized or improved without change in treatment or for which resection revealed radiation effects only. Clinical and conventional magnetic resonance (MR) parameters, including average percent change of rCBV and CBF, were evaluated as potential predictors of pseudoprogression. Parametric response map (PRM), an innovative, voxel-by-voxel method of image analysis, was also performed. Results: Median radiation dose was 72 Gy (range, 60 to 78 Gy). Of 27 patients, stable disease/partial response was noted in 13 patients and apparent progression was noted in 14 patients. Adjuvant temozolomide was continued in all patients. Pseudoprogression occurred in six patients. Based on PRM analysis, a significantly reduced blood volume (PRMrCBV) at week 3 was noted in patients with progressive disease as compared with those with pseudoprogression (P < .01). In contrast, change in average percent rCBV or rCBF, MR tumor volume changes, age, extent of resection, and Radiation Therapy Oncology Group recursive partitioning analysis classification did not distinguish progression from pseudoprogression. Conclusion: PRMrCBV at week 3 during chemoradiotherapy is a potential early imaging biomarker of response that may be helpful in distinguishing pseudoprogression from true progression in patients with high-grade glioma.
- 31 July 2009
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 19 (3) , 155-162
Functional and Metabolic Magnetic Resonance Imaging and Positron Emission Tomography for Tumor Volume Definition in High-Grade Gliomas
- 31 July 2009
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 19 (3) , 155-162
Functional and Metabolic Magnetic Resonance Imaging and Positron Emission Tomography for Tumor Volume Definition in High-Grade Gliomas